Abstract CT138: Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

Introduction: PF-06801591 is a humanized IgG4 monoclonal antibody that binds to the programmed cell death (PD-1) receptor and blocks its interaction with PD-1/2 ligands (PD-L1/2). In a phase 1 dose expansion study (NCT02573259), 106 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; n=68) or urothelial carcinoma (UC; n=38) were treated with PF-06891591 300 mg subcutaneously monthly. 12 patients with NSCLC (17.9%) and 7 with UC (18.4%) had a best overall response of partial response (PR). Response rates were higher in patients with high (≥1%) vs low ( Citation Format: Byoung Chul Cho, Konstantin Penkov, Igor Bondarenko, Joanna Pikiel, Hee Kyung Ahn, Alison Forgie, Ira Jacobs, Vinicius Bonato, Xinmeng Jasmine Mu, Keith Ching, Jeffrey Chou, Melissa L. Johnson. Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT138.